Clioquinol + Fluocinolone Acetonide interactions
Checked as Clioquinol (topical) + Fluocinolone acetonide in this data source.
Full monograph for Clioquinol + Fluocinolone AcetonideCheck it against another medicine
Medicines
64 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Acarbosevia Fluocinolone acetonide | Minor | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use… | 8 sources — open the full entry |
| Alogliptin Benzoatevia Fluocinolone acetonide | Minor | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use… | 8 sources — open the full entry |
| Biphasic Insulin Aspartvia Fluocinolone acetonide | Minor | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use… | 8 sources — open the full entry |
| Canagliflozin Hemihydratevia Fluocinolone acetonide | Minor | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use… | 8 sources — open the full entry |
| Dapagliflozin Propanediolvia Fluocinolone acetonide | Minor | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use… | 8 sources — open the full entry |
| Dulaglutidevia Fluocinolone acetonide | Minor | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use… | 8 sources — open the full entry |
| Empagliflozinvia Fluocinolone acetonide | Minor | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use… | 8 sources — open the full entry |
| Empagliflozin + Linagliptinvia Fluocinolone acetonide | Minor | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…2 documented mechanisms | 8 sources — open the full entry |
| Empagliflozin + Metformin Hydrochloridevia Fluocinolone acetonide | Minor | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…2 documented mechanisms | 8 sources — open the full entry |
| Ertugliflozinvia Fluocinolone acetonide | Minor | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use… | 8 sources — open the full entry |
| Glibenclamidevia Fluocinolone acetonide | Minor | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use… | 8 sources — open the full entry |
| Glimepiridevia Fluocinolone acetonide | Minor | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use… | 8 sources — open the full entry |
| Glimepiride + Metforminvia Fluocinolone acetonide | Minor | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…2 documented mechanisms | 8 sources — open the full entry |
| Glipizidevia Fluocinolone acetonide | Minor | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use… | 8 sources — open the full entry |
| Glipizide + Metformin Hydrochloridevia Fluocinolone acetonide | Minor | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…2 documented mechanisms | 8 sources — open the full entry |
| Insulin Aspartvia Fluocinolone acetonide | Minor | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use… | 8 sources — open the full entry |
| Insulin Aspart + Insulin Aspart Protaminevia Fluocinolone acetonide | Minor | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…2 documented mechanisms | 8 sources — open the full entry |
| Insulin Aspart [Protamine Crystallised]via Fluocinolone acetonide | Minor | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use… | 8 sources — open the full entry |
| Insulin Degludecvia Fluocinolone acetonide | Minor | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use… | 8 sources — open the full entry |
| Insulin Degludec + Insulin Aspart Premixedvia Fluocinolone acetonide | Minor | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…2 documented mechanisms | 8 sources — open the full entry |
| Insulin Detemirvia Fluocinolone acetonide | Minor | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use… | 8 sources — open the full entry |
| Insulin Glarginevia Fluocinolone acetonide | Minor | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use… | 8 sources — open the full entry |
| Insulin Glulisinevia Fluocinolone acetonide | Minor | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use… | 8 sources — open the full entry |
| Insulin Human [rDNA]via Fluocinolone acetonide | Minor | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use… | 8 sources — open the full entry |
| Insulin Lisprovia Fluocinolone acetonide | Minor | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use… | 8 sources — open the full entry |
| Insulin Lispro Protamine + Insulin Lisprovia Fluocinolone acetonide | Minor | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…2 documented mechanisms | 8 sources — open the full entry |
| Linagliptinvia Fluocinolone acetonide | Minor | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use… | 8 sources — open the full entry |
| Linagliptin + Metformin Hydrochloridevia Fluocinolone acetonide | Minor | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…2 documented mechanisms | 8 sources — open the full entry |
| Liraglutidevia Fluocinolone acetonide | Minor | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use… | 8 sources — open the full entry |
| Metformin Hydrochloridevia Fluocinolone acetonide | Minor | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use… | 8 sources — open the full entry |
| Miglitolvia Fluocinolone acetonide | Minor | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use… | 8 sources — open the full entry |
| Pioglitazonevia Fluocinolone acetonide | Minor | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use… | 8 sources — open the full entry |
| Pioglitazone + Glimepiridevia Fluocinolone acetonide | Minor | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…2 documented mechanisms | 8 sources — open the full entry |
| Pioglitazone + Metformin Hydrochloridevia Fluocinolone acetonide | Minor | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…2 documented mechanisms | 8 sources — open the full entry |
| Regular Insulin Human + Isophane Insulin Humanvia Fluocinolone acetonide | Minor | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use… | 8 sources — open the full entry |
| Repaglinidevia Fluocinolone acetonide | Minor | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use… | 8 sources — open the full entry |
| Saxagliptinvia Fluocinolone acetonide | Minor | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use… | 8 sources — open the full entry |
| Semaglutidevia Fluocinolone acetonide | Minor | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use… | 8 sources — open the full entry |
| Sitagliptinvia Fluocinolone acetonide | Minor | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use… | 8 sources — open the full entry |
| Sitagliptin + Metformin Hydrochloridevia Fluocinolone acetonide | Minor | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…2 documented mechanisms | 8 sources — open the full entry |
| Tirzepatidevia Fluocinolone acetonide | Minor | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use… | 8 sources — open the full entry |
| Vildagliptin + Metformin Hydrochloridevia Fluocinolone acetonide | Minor | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use… | 8 sources — open the full entry |
Conditions
Conditions in which Clioquinol + Fluocinolone Acetonide needs care, as documented in this source.
Hypothyroidism
ModeratePercutaneous absorption of clioquinol topical occurs. Protein-bound serum iodine levels may be increased during treatment with clioquinol topical and may interfere with certain thyroid function tests. Therapy with clioquinol topical should be used cautiously in patients with thyroid dysfunction.
1 source
- "Product Information. Vioform (clioquinol topical)." Ciba-Geigy Pharmaceuticals, East Hanover, NJ.
Toxic Optic Neuropathy
ModerateThe use of oral clioquinol (no longer marketed in the U.S.), generally at high dosages for prolonged periods, has resulted in ocular and neurologic toxicity, including optic neuritis, optic atrophy, and subacute myelo-optic neuropathy. Because the drug is systemically absorbed following topical administration to the skin, therapy with topical clioquinol should be administered cautiously in patients with peripheral neuropathy, optic neuritis, or preexisting visual defects. The use of occlusive dressings may substantially increase percutaneous absorption and should be avoided. All patients should be advised to immediately discontinue the drug and contact a physician if visual disturbances occur or are exacerbated during therapy. Clioquinol is not recommended for use in children and is contraindicated for those under 2 years of age.
1 source
- "Product Information. Vioform (clioquinol topical)." Ciba-Geigy Pharmaceuticals, East Hanover, NJ.